Cheaper but at what price? Example of decrementally cost-effectiveness analysis comparing multi-gene assays in breast cancer
May 2019

 

Clinical and economic impact of initiating dimethyl fumarate versus glatiramer acetate in patients with relapsing-remitting multiple sclerosis in EUROPE
May 2019

 

Clinical and economic impact of initiating dimethyl fumarate versus other disease modifying therapies in patients with relapsing-remitting multiple sclerosis in Germany
May 2019

 

Estimation of the Resource Utilization and Costs of Cytokine Release Syndrome Observed in the Transcend-NHL clinical trial: a micro-costing study
May 2019

 

Why advancing data visualization dogma is our best tool in disambiguating research findings
May 2019

 

Economic burden of bloodstream infection among those who survive or die during the inpatient hospitalization: analysis of 2015 National Inpatient Sample
December 2018

 

Health economic value of plazomicin versus colistin in the treatment of carbapenem-resistant enterobacteriaceae bloodstream infections: a cost-effectiveness analysis
December 2018

 

Health economic value of plazomicin versus meropenem in the treatment of complicated urinary tract infections including acute pyelonephritis: cost-effectiveness analysis
December 2018

 

Burden of cytokine release syndrome (CRS) and neurologic events (NE) in patients (Pts) with relapsed/refractory non-Hodgkin lymphoma (NHL) receiving lisocabtagene maraleucel (Liso-cel; JCAR017) in TRANSCEND NHL 001
November 2018

 

Estimating the health economic outcomes of serum 25-hydroxyvitamin D and intact parathyroid hormone levels in stage 3-4 CKD: The impact of treatment timing
October 2018